Open access
136
Views
17
CrossRef citations to date
0
Altmetric
Clinical Trial Report
Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
Dave Singh1 Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK, [email protected]Correspondence[email protected]
, Leonardo M Fabbri2 Section of Cardiorespiratory and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy;3 COPD Center, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden
, Stefano Vezzoli4 Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy
, Stefano Petruzzelli4 Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy
& Alberto Papi2 Section of Cardiorespiratory and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
Pages 531-546
|
Published online: 28 Feb 2019
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.